The novel adipokine Placin regulates glucose homeostasis via insulin secretion and IGF1 receptor signaling.
Lo TH., Chan KY., Chen D., Deng CJ., Ting-Yuan Yeh S., Wu M.
Animal Study on Type 1 Diabetes, published in Mol Ther (2026) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Animal Study
- Journal
- Mol Ther (2026)
- Country
- United States
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 42130086
- DOI
- 10.1016/j.ymthe.2026.05.006
Abstract (original English)
While genome-wide association studies have linked the human PLAC9 gene to body mass index, its physiological function remains largely unexplored. This study identifies PLAC9 as a novel adipokine that is enriched in the stromal vascular fraction of adipose tissue. Its circulating levels correlate with key metabolic dysregulation markers in humans and mice. We utilized gain- and loss-of-function approaches in diet-induced obesity (DIO) and streptozotocin (STZ)-induced diabetic mouse models to demonstrate that PLAC9 is a critical regulator of systemic metabolism. Notably, knockdown of endogenous PLAC9 exacerbated metabolic impairments, while its overexpression significantly mitigated DIO-associated metabolic dysregulation. Additionally, recombinant PLAC9 protein administration alleviated hyperglycemia in insulin-resistant and insulin-deficient models. Mechanistically, PLAC9 potentiated calcium-dependent insulin secretion in pancreatic beta cells, promoted glucose uptake in the liver and skeletal muscle, and upregulated hepatic Ghr and Igf1 levels to facilitate glucose homeostasis. Based on these hormone-like properties, we propose renaming the protein Placin. Collectively, these findings establish Placin as a promising therapeutic target, offering translational potential for the management of both type 2 and type 1 diabetes.
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.
Related research
- Level AMeta-analysisEurope PMC
Transforming hypoglycemia prediction in adult type 1 diabetes: a systematic review and meta-analysis for precision care
Meta-analysis on Type 1 Diabetes, published in Open Life Sci (2026) — summary generated from the PubMed abstract.
- 2026
Open Life Sci - Level ASystematic ReviewEurope PMC
Long-term storage, cryopreservation, and culture of isolated human islets: a systematic review
Systematic Review on Type 1 Diabetes, published in Front Transplant (2025) — summary generated from the PubMed abstract.
- 2025
Front Transplant - Level AMeta-analysisEurope PMC
Change in Viability and Function of Pancreatic Islets after Coculture with Mesenchymal Stromal Cells: A Systemic Review and Meta-Analysis
Meta-analysis on Type 1 Diabetes, published in J Diabetes Res (2020) — summary generated from the PubMed abstract.
- 2020
J Diabetes Res7 citations - Level AMeta-analysisEurope PMC
Stem cell therapy for patients with diabetes: a systematic review and meta-analysis of metabolomics-based risks and benefits
Meta-analysis on Type 1 Diabetes, Type 2 Diabetes, published in Stem Cell Investig (2018) — summary generated from the PubMed abstract.
- 2018
Stem Cell Investig22 citations - Level AMeta-analysisEurope PMC
Clinical Efficacy of Stem Cell Therapy for Diabetes Mellitus: A Meta-Analysis
Meta-analysis with a reported sample of 524 on Type 1 Diabetes, published in PLoS One (2016) — summary generated from the PubMed abstract.
- 2016
- n = 524
PLoS One81 citations - Level BClinical TrialEurope PMC
Stem Cell-Derived Beta-Cell Therapies: Encapsulation Advances and Immunological Hurdles in Diabetes Treatment
Clinical Trial on Type 1 Diabetes, Type 2 Diabetes, Scar, published in Cells (2026) — summary generated from the PubMed abstract.
- 2026
Cells1 citations